Upregulation of the mevalonate pathway enzymes including HMGCR was found in breast apocrine cysts, DMBA- and MNU- initiated mammary tumors, breast cancer stem cell-derived basal/mesenchymal tumorspheres, and Tamoxifen-resistant breast cancer. This evidence concerns the gene HMGCR and breast carcinoma.